ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference
September 22, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021 07:30 ET
|
ContraFect Corporation
Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Company’s DLA portfolio Continued patient enrollment in ongoing...
ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID
July 19, 2021 07:31 ET
|
ContraFect Corporation
YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity
July 19, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development
June 17, 2021 07:31 ET
|
ContraFect Corporation
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum
June 17, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections
May 26, 2021 07:30 ET
|
ContraFect Corporation
Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function The observed clinical responses in patients...
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021 07:30 ET
|
ContraFect Corporation
Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase...
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
May 03, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Invited to Participate in the Cystic Fibrosis Target Product Profile Virtual Symposium
April 26, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., April 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...